Podcast Summary: Tomorrow's Cure – 3D Bioprinted Skin: Breakthroughs in Regenerative Medicine

Podcast: Mayo Clinic On Human Optimization (Episode from "Tomorrow’s Cure")
Date: March 18, 2026
Host: Kathy Werzer
Guests: Dr. Sarenya Wiles (Dermatologist, Mayo Clinic), Dr. Adam Feinberg (Biomedical Engineer, Carnegie Mellon University)

Episode Overview

This episode explores rapid advancements in 3D bioprinting of human skin—a technology that promises to revolutionize regenerative medicine, wound care, and our understanding of skin aging and disease. Dr. Sarenya Wiles and Dr. Adam Feinberg discuss how their labs are building layered living skin models using human cells and collagen, the implications for diagnostics and therapeutics (especially for burns and chronic wounds), and what senescent ‘zombie cells’ teach us about aging. The episode also explores democratizing access to bioprinting technology, ethical considerations, and the promise of making medicine more inclusive and patient-specific.

Key Discussion Points & Insights

1. Understanding "Skin Span" and Its Importance

• Skin span applies the concepts of lifespan and healthspan to skin, emphasizing not just how long it lasts but how well it functions as a barrier, regulator, and mirror of overall health (03:06).
• Dr. Wiles: “Skin span is the concept that we can have optimally functioning skin at the level of structure, but also at the level of its function… The idea is that how do we better keep our skin health optimized?” (03:06)

2. Skin as a Reflection of Systemic Health

• The skin reveals much about overall health, and signs of disease, stress, or sleep deprivation can be visible on the skin (03:52).
• Dr. Wiles: “I consider the skin as a mirror to your systemic health… it is your external facing barrier. It can impact a lot of ways that our systemic aging is occurring.” (03:52)

3. The Science of 3D Bioprinted Skin

• Layers: The effort is to "model the cake layers"—epidermis, dermis, hypodermis—each with unique cells and functions (01:06; 07:35).
• Bioprinting Approach: Using "native human tissue as our bioprint" to replicate natural skin structure and function.
• Printing Material: Focus on biological—not synthetic—materials (cells, collagen, hyaluronic acid), which may offer better integration with the human body (06:07; 06:23).
• Dr. Feinberg: “Our system is really designed to work with entirely biologic materials. And therefore what we create is entirely biologic. The beauty of that is that hopefully it functions more similar to the native tissue...” (06:23)
• Collagen’s Role: Collagen is the scaffolding of skin and vital in constructing functional tissue that looks and acts like the real thing (10:33).

4. Applications & Potential of 3D Skin Models

• Replacement for animal testing: Promising for preclinical drug and therapy testing, potentially speeding up safe product development and providing more human-relevant data (09:26).
• Example: Delays in mini-pig models led Dr. Wiles’ lab to develop 3D human skin models instead (09:26).
• Suited for personalized diagnostics and therapeutics, including chronic wounds, burns, and rare disease models (15:11; 27:11).

5. Vascularization, Innervation, and Realism

• Creating realistic tissue also means replicating blood vessels and nerve networks to maintain cell survival and sensory function (13:33).

6. Impact for Burn Victims and Wound Care

• The ultimate goal is to produce functional skin grafts and wound patches that can integrate well into patients, particularly those with poor natural healing (15:11).
• Dr. Feinberg describes creating tailor-made constructs using imaging and “bioinks” from decellularized tissue (16:06).

7. Senescent ("Zombie") Cells and Aging

• Senescent cells: Cells that stop dividing but don’t die, playing a useful role initially in cancer prevention but contributing to aging and inflammation if they accumulate (18:15).
• Dr. Wiles: “So zombie cells, or senescent cells, are cells that basically obtain a cell cycle arrest. They are no longer dividing, but they don't die off… over time … we don't clear these cells as well.” (18:15)
• Senescent cells’ secretions (SASP) create systemic "noise," influencing other organs and even potentially cognition (19:56).

8. Personalized Disease Modeling & Predictive Medicine

• By making “patient-on-a-chip” models—using patient-specific cells—researchers aim to predict individual therapeutic responses (20:52).
• Example: Dr. Feinberg’s lab demonstrated that chemotherapy-induced heart failure could be modeled and predicted using 3D-printed heart tissue with patient stem cells (20:52).

9. Validation, Challenges, and FDA Interest

• Validation is complex and expensive—with rigorous testing required to prove accuracy and reproducibility (23:09).
• Dr. Feinberg: “The FDA is really interested in moving away from animal models and moving to these engineered human tissue models. So there's a lot of support that continues to be moved into that space.” (24:15)

10. Ethics, Equity, and Accessibility

• Models allow for greater inclusivity (different skin types and pigmentation) and open access to rare disease testing (25:51; 27:11).
• Affordability and reproducibility are key for wide adoption.

11. Democratizing Bioprinting: Open Source and Education

• Dr. Feinberg’s lab runs workshops to teach others to build low-cost bioprinters (as low as $1,000), increasing access and accelerating research (29:00).
• “Innovation does not need to be expensive. I think innovation really comes actually from folks like my lab working with folks like Dr. Wiles lab, really combining the clinical problems with … advanced engineering solutions...” (32:46)

12. Barriers to Clinical Adoption

• Need to precisely define medical problems for targeted innovation (33:46).
• Demonstrating real-world clinical wins will drive funding, regulatory change, and industry engagement (34:29).
• Scaling manufacturing by learning from other industries (auto, aerospace) and leveraging AI.

13. Looking Ahead: Motivation and Vision

• Both Dr. Feinberg and Dr. Wiles are driven by the opportunity to fundamentally change lives through building new tissues and organs, and making healthcare solutions more accessible and inclusive (37:12; 39:13).
• Dr. Feinberg: “We already know that transplanted organs work 100% … once we can start doing that [with bioprinting] … we’re off to the races. Really what motivated me though was we're fundamentally changing, you know, medicine and human longevity as we know it, if this becomes capable.” (37:12)

Notable Quotes & Timestamps

• Dr. Wiles, on skin span:
  “Skin span is the concept that we can have optimally functioning skin at the level of structure, but also at the level of its function of thermoregulation and serving as a barrier preventing from infection longer.” (03:06)
• Dr. Feinberg, on materials:
  “Our system is really designed to work with entirely biologic materials. And therefore what we create is entirely biologic.” (06:23)
• Dr. Wiles, on inclusivity:
  “Clinical trials are not as inclusive…this is an opportunity to try to start inclusivity much earlier on and try to get different types of pigmented skin models to test at the level of the preclinical diagnostic testing platform.” (25:51)
• Dr. Feinberg, on democratization:
  “Ours [3D bioprinter] cost $1000 at most, and I would argue they outperform all the others pretty substantially if you know how to use it properly…once the intimidation of the technology, I think, starts to melt away, you’re really able to now focus on layering whatever innovation you want on top of it…” (29:00; 32:46)
• Dr. Feinberg, on vision:
  “If we can start to replace organs, you know, we've fundamentally shifted human lifespan, human quality of life. It's hard to have more impact than that on society.” (37:12)

Timestamps for Important Segments

• [01:06] – Modeling skin as cake layers; intro to bioprinting approaches
• [03:06] – Defining “skin span” vs healthspan/lifespan
• [06:07] – Materials used in 3D printing: why collagen, why not synthetic?
• [09:26] – Application: preclinical drug testing; story of moving beyond animal models
• [10:33] – Importance of collagen as a scaffold and enabling vascularization
• [13:33] – Challenges in reproducing skin structure, vascularization, innervation
• [15:11] – Burn injuries, wound patch therapeutic applications
• [18:15] – Senescent (zombie) cells and their impact on skin aging and healing
• [20:52] – Personalized disease modeling: chemo-induced heart failure as case study
• [23:09] – Validation issues and the FDA perspective
• [25:51] – Ethical, inclusivity, accessibility arguments for bioprinted skin
• [29:00] – Open source workshops for building bioprinters
• [33:46] – Barriers to clinical adoption/future directions
• [37:12, 39:13] – What inspires the guests: impact on medicine and patients

Memorable Moments

• The analogy of “cake layers” to describe skin’s structure (01:06; 07:35).
• The practical benefits of open-source, low-cost bioprinters—empowering both top researchers and K–12 students (29:00–32:46).
• Linking cellular aging in the skin to systemic health and cognition (19:56).
• Emotional motivation: helping patients who “have to wear their skin disease” (39:13).

Conclusion

This conversation reveals that the future of skin—and regenerative medicine more broadly—is being pieced together at the intersection of engineering, biology, and clinical need. 3D bioprinting of skin is more than sci-fi; it's unfolding rapidly, with potential to transform therapies for burns, wounds, aging, and rare diseases. Ethical, economic, and inclusivity questions remain central, but the democratization of technology and the dedication of interdisciplinary teams are pushing this future ever closer.